Close Menu

NEW YORK – The GenomeWeb Index rose 3 percent in September, rebounding from a 4 percent loss in August and outperforming the broader markets, which were awash in volatility as they reacted to continued uncertainty in US presidential politics.

The index outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which fell more than 2 percent, more than 5 percent, and a fraction of a percent, respectively. Individual stock performances in the GenomeWeb Index were positive in September, as 24 of the 37 stocks saw gains and 13 saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.